Newsletter | March 31, 2026

03.31.26 -- AI For NAM-Ready Drug Development: Turning Promise Into Trust

FEATURED EDITORIAL

New Approach Methods In Practice: Where Are We Today?

NAMs have moved beyond a technological promise, but now the current challenge is to operationalize their adoption.

AI For NAM-Ready Drug Development: Turning Promise Into Trust

AI is naturally situated for NAMs, and its value will be maximized when it is deployed as part of a rigorously validated, evidence-based strategy.

INDUSTRY INSIGHTS

Automated Library Prep For Nanopore Human Whole Genome Sequencing

Gain insight into an automated high‑input workflow that streamlines long‑read whole‑genome library prep, supporting large DNA fragments while reducing reagent use.

Accelerating Clinical Development: Modern Tools In Process Chemistry

Whether you aim to address bottlenecks or explore advanced techniques, gain a practical and forward-thinking perspective to streamline early-phase development with HTE and model-based approaches.

Media Selection For In Vitro Testing Of Poorly Soluble Drugs

Scientist Deanna Mudie, Ph.D., covers the design of dissolution media to support biopredictive dissolution testing and how the properties of a drug and formulation affect performance.

Five Practical Considerations To Move From Concept To Clinic

Learn more about five key factors for advancing targeted in vivo LNP programs, from formulation and targeting strategies to bioanalytical readiness and scalability.

Rapid And Sensitive Detection Of Replication-Competent Lentivirus (RCL)

See how a rapid digital PCR workflow enables reliable detection of trace RCL levels while maintaining strong performance in complex samples, which support more confident decisions in manufacturing.

SOLUTIONS

Expediting Drug Discovery From Concept To Commercialization

Advanced Performance And Fluorochrome Flexibility